Quest Diagnostics Inc (DGX) · Oct 6, 2026 · Exec change

Quest Diagnostics executive change keeps Nova leader through 2027

Executive transition — Retirement July 2027; new executive role effective November 1, 2026

Quest Diagnostics’ executive change sets a July 2027 retirement while retaining Catherine Doherty to lead health-system and Project Nova work.

Quest Diagnostics is expanding its health-system relationships while undertaking Project Nova, a multi-year overhaul of its order-to-cash systems and processes; the first implementation wave is planned for fall 2027. This is an orderly transition, not an abrupt departure. Catherine Doherty will retire in July 2027. 〔0〕 Until then, she moves into an executive vice president role focused on health systems, the Corewell Health joint venture, and Project Nova, effective November 1, 2026. 〔1〕

The business signal is continuity through a strategically important buildout. Keeping Doherty attached to the health-system portfolio and Nova reduces the immediate execution gap around two initiatives that Quest is actively scaling, but the filing does not name a successor or explain how responsibilities will be divided after her retirement.

The compensation package reinforces retention rather than signaling a change in strategy. Quest keeps her $650,000 base salary and 80% target incentive, while granting $1.2 million of restricted stock units; that looks designed to keep leadership continuity through the transition, though it also adds compensation cost without providing a new operating milestone.

Bottom line: This is a managed executive handoff that preserves leadership on Quest’s health-system and Project Nova work for now. It matters operationally, but is mixed rather than clearly favorable because the filing provides continuity without resolving the longer-term succession question.

What to watch next

Doherty retirement, July 2027

Original filing on SEC EDGAR

More Quest Diagnostics Inc news

Quest Diagnostics executive change keeps Nova leader through 2027 | DGX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.